Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Clinical Outcomes and Health-Related Quality of Life (HRQoL) Among Randomized Clinical Trial (RCT)-Eligible and RCT-Ineligible Patients: Results from the Connect ® MM Registry

Lynne I. Wagner, PhD, Kathleen Toomey, MD, Sikander Ailawadhi, MD, Sundar Jagannath, Cristina Gasparetto, MD, Brian G.M. Durie, MD, Mohit Narang, MD, Robert M. Rifkin, MD, Howard R. Terebelo, DO, James L. Omel, MD, James W. Hardin, PhD, Hans C. Lee, MD, Shankar Srinivasan, PhD MBA, Liang Liu, MS, Mazaher Dhalla, PharmD, Donna Catamero, ANP-BC, OCN, CCRC, Rafat Abonour, MD

Blood (2019) 134 (Supplement_1): 1843.

https://doi.org/10.1182/blood-2019-126143

Published: 2019

Journal Articles

Nutrition Access in Adult Sickle Cell Patients: An Exploratory Study

Sarah Agamah, MBA, MPH

Blood (2019) 134 (Supplement_1): 3472.

https://doi.org/10.1182/blood-2019-130505

Published: 2019

Journal Articles

Characteristics of Inferior Vena Cava Filter Placement, Management, and Retrieval at a Multi-Center Institution

Charis Durham, MD, Kelsey Reely, DO, Wencong Chen, PhD, Lucas Wong, MD, Bryce Betteridge, MD

Blood (2019) 134 (Supplement_1): 1157.

https://doi.org/10.1182/blood-2019-124856

Published: 2019

Journal Articles

Using Healthcare Claims Data to Analyze the Prevalence of Chronic Myeloid Leukemia in France: A Nationwide Population-Based Study

Stephanie Foulon, MD, Pascale Cony-Makhoul, MD PhD, Agnes Guerci-Bresler, MD PhD, Marc Delord, PhD, Eric Solary, MD PhD, Alain Monnereau, MD PhD, Julia Bonastre, PhD, Pascale Tubert Bitter, PhD

Blood (2018) 132 (Supplement 1): 3015.

https://doi.org/10.1182/blood-2018-99-111489

Published: 2018

Journal Articles

Duration of Therapy (DOT) and Time to Next Therapy (TTNT) of Bortezomib, Carfilzomib and Ixazomib Combinations with Lenalidomide/Dexamethasone (VRd, KRd, IRd) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Clinical Practice in the United States Vs Clinical Trial Experience

Ajai Chari, MD, Dorothy Romanus, Katarina Luptakova, MD, Aditya Raju, MS, Eileen Farrelly, MPH, Marlo Blazer, PharmD, Tomas Skacel, MD, Parameswaran Hari, MD MRCP, MS

Blood (2017) 130 (Supplement 1): 1818.

https://doi.org/10.1182/blood.V130.Suppl_1.1818.1818

Published: 2017

Journal Articles

Cost-Effectiveness of Daratumumab Plus Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: An Analysis of the Pollux Trial

Eric M Maiese, Christopher N Graham, Emma Hawe, Jean-Gabriel Le Moine, Ivo Abraham, PhD RN, Mekre Senbetta

Blood (2017) 130 (Supplement 1): 4711.

https://doi.org/10.1182/blood.V130.Suppl_1.4711.4711

Published: 2017

Journal Articles

Efficacy of Iron Therapy on Fatigue and Work Capacity in Non-Anemic Iron Deficient Adults: A Systematic Review of Randomized Controlled Trials

Brett L. Houston, MD, Daryl Hurrie, MSc, Jeff Graham, MD, Brittany Perija, MD, Emily Rimmer, MD, Rasheda Rabbani, PhD, Charles N. Bernstein, MD, Alexis Turgeon, MD, Dean Fergusson, PhD, Donald S. Houston, MD PhD, Ahmed M. Abou-Setta, MD PhD, Ryan Zarychanski, MD

Blood (2017) 130 (Supplement 1): 3497.

https://doi.org/10.1182/blood.V130.Suppl_1.3497.3497

Published: 2017

Journal Articles

Cost-Effectiveness of Daratumumab Plus Bortezomib and Dexamethasone Versus Bortezomib Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: An Analysis of the Castor Trial

Eric M Maiese, Christopher N Graham, Emma Hawe, Jean-Gabriel Le Moine, Ivo Abraham, PhD RN, Mekre Senbetta

Blood (2017) 130 (Supplement 1): 3400.

https://doi.org/10.1182/blood.V130.Suppl_1.3400.3400

Published: 2017

Journal Articles

Demographic Differences Between Unselected Patients and Participants of Multiple Myeloma Clinical Trials in the US: A Threat to External Validity

Luciano J Costa, MD PhD, Parameswaran Hari, MD MRCP, MS, Shaji Kumar, MD

Blood (2015) 126 (23): 634.

https://doi.org/10.1182/blood.V126.23.634.634

Published: 2015

Journal Articles

Assessment and Validation of the EQ-5D Among a Population of Myeloproliferative Neoplasm Patients

Robyn M. Scherber, MD MPH, Steven Knapper, Sonia Fox, Heidi E. Kosiorek, MS, Marzia Shah, Sepehr Abdi-Moradi, Adam J Mead, Amylou C. Dueck, PhD, Samah Ailman, Anthony R Green, PhD FRCP, FRCPath, Marion Wood, FRCP, FRCPath, Joanne Ewing, PhD BMBS, BSc, FRPATH,, Fredrick Chen, Jason Coppell, Mary Frances McMullin, MD FRCPath, FRCP, Holly Geyer, MD, Ruben A. Mesa, Claire N. Harrison

Blood (2015) 126 (23): 5179.

https://doi.org/10.1182/blood.V126.23.5179.5179

Published: 2015

Journal Articles

Irish Hospitals Meet Proposed International Guidelines For Non-Hodgkin Lymphoma Management, But Areas For Improvement Remain

Rory Crotty, Maeve P Crowley, MB BCh BAO, Mary R Cahill, MD FRCPath, Brian R Healey Bird, MB, FRCP

Blood (2013) 122 (21): 5591.

https://doi.org/10.1182/blood.V122.21.5591.5591

Published: 2013

Journal Articles

Do Results From Clinical Trials in Acute Myeloid Leukemia Reflect Clinical Reality? A Danish National Cohort Study of 813 Patients

Lene Sofie Granfeldt Ostgard, MD, Mette Nørgaard, MD, Henrik Sengeløv, MD, PhD, Lars Kjeldsen, MD, PhD, Lone S. Friis, MD, PhD, Morten K. Jensen, MD, Maria Kallenbach, MD, Jan M. Norgaard, MD, PhD

Blood (2012) 120 (21): 1477.

https://doi.org/10.1182/blood.V120.21.1477.1477

Published: 2012

Journal Articles

Chemotherapy for Acute Myeloid Leukemia Can Compensate Other Adverse Prognostic Factors in Elderly: A Retrospective Longitudinal Cohort Study in a Local Community, Japan

Osamu Imataki, MD, Hiroaki Ohnishi, MD, Yasunori Kawachi, M.D., Makoto Ide, M.D., Ph.D., Makiko Uemura, M.D., Kimihiro Kawakami, M.D., Ph.D., Akihito Matsuoka, M.D., Ph.D., Masato Waki, M.D., Ph.D., Hidetaka Takimoto, MD, Yasuo Hoshijima, M.D., Ph.D., Tetsuya Fukumoto, M.D., Ph.D., Kensuke Matsumoto, M.D., Ph.D., Fusako Waki, MD, Teruhisa Taoka, M.D., Ph.D., Takuya Matsunaga, MD, PhD

Blood (2012) 120 (21): 3582.

https://doi.org/10.1182/blood.V120.21.3582.3582

Published: 2012

Journal Articles

Acceptability and Validity of Use of a Patient-Reported Cost Diary To Capture Health Resource Utilization and Costs Associated with Deep Venous Thrombosis and Post-Thrombotic Syndrome.

Wissam El-Hadi, BSc, Thierry Ducruet, MSc, Mira Johri, PhD, Susan R. Kahn, MD FRCPC MSc

Blood (2007) 110 (11): 5173.

https://doi.org/10.1182/blood.V110.11.5173.5173

Published: 2007

Journal Articles

A Predictive Model for Tumor Lysis Syndrome in Acute Myelogenous Leukemia.

Anthony R. Mato, MD, Brett E. Riccio, MD, Li Qin, PhD, Daniel Heitjan, PhD, Alison Loren, MD, Martin Carroll, MD, David Porter, MD, Donald Tsai, MD, Edward Stadtmauer, MD, Sasha Perl, MD, Alan Gewirtz, MD, Sunita Nasta, MD, Stephen Schuster, MD, Steven Goldstein, MD, Selina M. Luger, MD

Blood (2004) 104 (11): 883.

https://doi.org/10.1182/blood.V104.11.883.883

Published: 2004

NARROW

Clinical Outcomes and Health-Related Quality of Life (HRQoL) Among Randomized Clinical Trial (RCT)-Eligible and RCT-Ineligible Patients: Results from the Connect ® MM Registry

Nutrition Access in Adult Sickle Cell Patients: An Exploratory Study

Characteristics of Inferior Vena Cava Filter Placement, Management, and Retrieval at a Multi-Center Institution

Using Healthcare Claims Data to Analyze the Prevalence of Chronic Myeloid Leukemia in France: A Nationwide Population-Based Study

Duration of Therapy (DOT) and Time to Next Therapy (TTNT) of Bortezomib, Carfilzomib and Ixazomib Combinations with Lenalidomide/Dexamethasone (VRd, KRd, IRd) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Clinical Practice in the United States Vs Clinical Trial Experience

Cost-Effectiveness of Daratumumab Plus Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: An Analysis of the Pollux Trial

Efficacy of Iron Therapy on Fatigue and Work Capacity in Non-Anemic Iron Deficient Adults: A Systematic Review of Randomized Controlled Trials

Cost-Effectiveness of Daratumumab Plus Bortezomib and Dexamethasone Versus Bortezomib Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: An Analysis of the Castor Trial

Demographic Differences Between Unselected Patients and Participants of Multiple Myeloma Clinical Trials in the US: A Threat to External Validity

Assessment and Validation of the EQ-5D Among a Population of Myeloproliferative Neoplasm Patients

Irish Hospitals Meet Proposed International Guidelines For Non-Hodgkin Lymphoma Management, But Areas For Improvement Remain

Do Results From Clinical Trials in Acute Myeloid Leukemia Reflect Clinical Reality? A Danish National Cohort Study of 813 Patients

Chemotherapy for Acute Myeloid Leukemia Can Compensate Other Adverse Prognostic Factors in Elderly: A Retrospective Longitudinal Cohort Study in a Local Community, Japan

Acceptability and Validity of Use of a Patient-Reported Cost Diary To Capture Health Resource Utilization and Costs Associated with Deep Venous Thrombosis and Post-Thrombotic Syndrome.

A Predictive Model for Tumor Lysis Syndrome in Acute Myelogenous Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only